Application No.: 09/164,568 2 Docket No.: 20052/1200518-US5

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-68. (Canceled)
- 69. (Currently amended) A method for reducing T cell responsiveness *in vivo* to an autoantigen expressing cell, which method comprises administering to a subject in need of such treatment:
 - (a) an antigen-presenting cell that presents an autoantigen; and
 - (b) an anti-gp39 antibody which binds to an antigen, which antigen:
 - (i) is bound by MR1, wherein MR1 is a monoclonal antibody produced by a hybridoma having ATCC Accession No. HB 11048 a CD40-immunoglobulin (CD40-Ig) fusion protein;
 - (ii) is present on activated but not resting T-cells; and
 - (iii) has the same molecular weight as a protein precipitated by a CD40immunoglobulin (CD40-Ig) the CD40-Ig fusion protein,

wherein the anti-gp39 antibody is administered prior to, concurrent with, or subsequent to administration of the antigen-presenting cell in an amount effective to reduce T cell responsiveness to the antigen-presenting cell.

Application No.: 09/164,568 3 Docket No.: 20052/1200518-US5

70. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is selected from the group consisting of B lymphocytes, monocytes, dendritic cells, Langerhans cells, keratinocytes, endothelial cells, astrocytes, fibroblasts and oligodendrocytes.

- 71. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is a B lymphocyte.
- 72. (Previously presented) The method of claim 71, wherein the B lymphocyte is an activated B lymphocyte.
- 73. (Previously presented) The method of claim 72, wherein the activated B lymphocyte is a splenic activated B lymphocyte.
- 74. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is a lymphoid cell.
- 75. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is a peripheral blood lymphocyte.
- 76. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is a bone marrow lymphocyte.
- 77. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is a Langerhans cell.
- 78. (Previously presented) The method of claim 69, wherein the antigenpresenting cell is a dendritic cell.
- 79. (Previously presented) The method of claim 69, wherein the anti-gp39 antibody is an anti-human anti-gp39 antibody.

Application No.: 09/164,568 4 Docket No.: 20052/1200518-US5

80. (Previously presented) The method of claim 79, wherein the anti-human anti-gp39 antibody is humanized.

81. (Previously presented) The method of claim 79, wherein the anti-human anti-gp39 antibody is a chimeric anti-human anti-gp39 antibody containing human constant regions.